Suppl. Table 12.
The main PK parameters of astragaloside IV in rat plasma after oral administration of different formulations. (Mean ± SD, n = 6)
| Parameter | Group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| formulation 1 | formulation 2 | formulation 3 | formulation 4 | formulation 5 | formulation 6 | formulation 7 | formulation 8 | formulation 9 | |
| T1/2(h) | 12.16 ± 1.08 | 12.05 ± 1.13 | 8.25 ± 0.85 | 18.35 ± 0.96 | 10.87 ± 1.05 | 10.92 ± 1.21 | 12.34 ± 0.99 | 10.75 ± 0.46 | 7.82 ± 1.04 |
| Tmax(h) | 0.79 ± 0.09 | 0.70 ± 0.10 | 0.81 ± 0.06 | 3.04 ± 0.24 | 0.95 ± 0.04 | 1.06 ± 0.11 | 0.64 ± 0.04 | 0.94 ± 0.13 | 0.68 ± 0.02 |
| Cmax(μg/L) | 311.91 ± 23.01 | 217.12 ± 41.51 | 625.65 ± 66.48 | 196.7 ± 11.21 | 211.43 ± 19.96 | 1179.06 ± 223.25 | 2776.87 ± 336.44 | 836.11 ± 114.25 | 1037.03 ± 156.36 |
| AUC(0-t) (μg/L*h) | 1035.18 ± 144.44 | 729.53 ± 195.78 | 1562.07 ± 280.09 | 1547.56 ± 115.17 | 703.82 ± 124.45 | 7965.3 ± 634.17 | 10158.82 ± 1005.65 | 4010.21 ± 685.21 | 4753.63 ± 578.33 |
| MRT(0-t) (h) | 4.98 ± 0.68 | 4.97 ± 0.99 | 4.42 ± 0.86 | 8.11 ± 1.08 | 4.75 ± 0.11 | 7.9 ± 0.68 | 6.42 ± 0.75 | 6.35 ± 0.94 | 5.91 ± 0.77 |